Longitudinal Study of Neurodegenerative Disorders

Status Recruiting

Clinical Trial Summary

The purpose of this study is to understand the course of rare genetic disorders that affect the brain. This data is being analyzed to gain a better understanding of the progression of the rare neurodegenerative disorders and the effects of interventions.

Clinical Trial Description

Patients would be evaluated by a multidisciplinary team at specific time points every 3 months the first year, every 6 months the second year and once a year thereafter. ;

Study Design

Related Conditions & MeSH terms

ALD
Alpha-Mannosidosis
Batten Disease
Deficiency Diseases
GAN
Gangliosidoses
Gangliosidosis, GM1
Gaucher Disease
GM1 Gangliosidoses
GM3 Gangliosidosis
Krabbe Disease
Leukodystrophy
Leukodystrophy, Globoid Cell
Leukoencephalopathies
Lysosomal Storage Diseases
MLD
Morquio Disease
MPS I
MPS II
MPS III
MPS IV
Mucopolysaccharidosis IV
Multiple Sulfatase Deficiency Disease
Neurodegenerative Diseases
Neuronal Ceroid-Lipofuscinoses
Niemann-Pick Disease, Type C
Niemann-Pick Diseases
NP Deficiency
Osteopetrosis
Pelizaeus-Merzbacher Disease
Pick Disease of the Brain
PKAN
Purine Nucleoside Phosphorylase Deficiency
S-Adenosylhomocysteine Hydrolase Deficiency
Sandhoff Disease
Tay-Sachs Disease
Vanishing White Matter Disease

Clinical Trial Details

NCT number	NCT03333200
Study type	Observational
Source	University of Pittsburgh
Contact	Deepa Rajan, MD
Phone	412-692-8388
Email	rajands@upmc.edu
Status	Recruiting
Phase
Start date	January 11, 2012
Completion date	January 2035

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04189601` - Complement Activation in the Lysosomal Storage Disorders
Completed	`NCT04430881` - A National Study in Patients With Unexplained Splenomegaly
Completed	`NCT02536937` - A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT02536911` - A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate	Phase 1
Completed	`NCT01411228` - A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Phase 3
Terminated	`NCT04094181` - A Study of VPRIV in Participants With Gaucher Disease Previously Treated With Other Enzyme Replacement Therapies or Substrate Reduction Therapies
Completed	`NCT00391625` - Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)	Phase 1/Phase 2
Completed	`NCT03625882` - Survey Study for Velaglucerase Alfa (VPRIV) in Japan
Active, not recruiting	`NCT05526664` - Omics Gaucher Study: Multiomic Approach
Completed	`NCT02536755` - Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies	Phase 3
Recruiting	`NCT01344096` - Thrombocytopathy in Gaucher Disease Patients	N/A
Completed	`NCT01881633` - A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers	Phase 1
Recruiting	`NCT06116071` - Biomarkers Related to Bone in Pediatric Gaucher Disease
Recruiting	`NCT01951989` - Intra-monocyte Imiglucerase Kinetics in Gaucher Disease	Phase 2
Completed	`NCT00258778` - Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)	Phase 1
Recruiting	`NCT04388969` - World Data on Ambroxol for Patients With GD and GBA Related PD
Recruiting	`NCT05992532` - GammaGA: Prevalence of Acid Sphingomyelinase Deficiency Disease (ASMD) and Gaucher Disease in Patients With Monoclonal Gammopathies and/or Multiple Myeloma
Terminated	`NCT04145037` - Lentiviral Vector Gene Therapy - The Guard1 Trial of AVR-RD-02 for Subjects With Type 1 Gaucher Disease	Phase 1/Phase 2
Completed	`NCT00302146` - Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
Active, not recruiting	`NCT02605603` - SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease